Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MNKD with free AI briefings, catalyst countdowns, and dilution alerts.

MNKD · MANNKIND CORP

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$96.6M Cash on Hand
11mo Cash Runway
Follow MNKD by email Get an email when MNKD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MNKD, unsubscribe in one click. Privacy

📣 What MNKD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Technosphere® Insulin Inhalation System Diabetes N/A · NCT01459133 Withdrawn
Rapid-acting Insulin Analog Diabetes Mellitus, Type 1 Phase 4 · NCT05904743 Completed
Insulin Human Diabetes Mellitus, Type 1 Phase 4 · NCT05904743 Completed
Afrezza (insulin human) Inhalation Powder Type 1 Diabetes Phase 4 · NCT05243628 Completed
Afrezza Inhalant Product Type 2 Diabetes Treated With Insulin Phase 4 · NCT04125082 Unknown
Basal Insulin Diabetes Mellitus, Type 1 Phase 4 · NCT05904743 Completed
Technosphere® Insulin with MedTone C Inhaler Type 1 Diabetes Mellitus Phase 3 · NCT01445951 Completed
Technosphere Insulin Inhalation Powder Type 2 Diabetes Phase 3 · NCT01196104 Terminated
Technosphere ®Insulin with Gen2 Inhaler Type 1 Diabetes Mellitus Phase 3 · NCT01445951 Completed
Technosphere Insulin & Metformin Diabetes Mellitus, Type 2 Phase 3 · NCT00332488 Completed
Metformin & Secretagogues Diabetes Mellitus, Type 2 Phase 3 · NCT00332488 Completed
Insulin Aspart in combination with a basal… Type 1 Diabetes Mellitus Phase 3 · NCT01445951 Completed
Inhaled Technosphere Insulin Diabetes, Gestational Phase 2/3 · NCT06535789 Completed
Technosphere Powder Type 2 Diabetes Phase 3 · NCT01451398 Completed
Clofazimine Inhalation Suspension MAC Lung Disease Phase 3 · NCT06418711 Terminated
Active Comparator: 6.0mg GRI-0621 Diabetes, Type I Phase 3 · NCT00308308 Completed

Also used in these trials (approved or third-party drugs, not MNKD's own candidates): Insulin Degludec, Insulin Aspart, Insulin Lispro, Insulin Glargine, Methacholine Chloride.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MNKD holds $96.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $26.5M/quarter from operations, an estimated runway of 11 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MNKD files for a raise →

👥 Who Owns MNKD

Insiders 2.1% Institutions (326 holders) 56.6% Public and other holders 41.3%
HolderTypeShares% of sharesAs of
Rubric Capital Management LP Institution (13G, 5%+) 18,000,000 5.60% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 15,450,421 4.80% 2026-06-30
Michael Castagna
Chief Executive Officer, Director · +877,275 options
Insider 2,433,779 0.76% 2026-07-15
Stuart A Tross
Chief People & Workpl Officer · +265,143 options
Insider 1,058,142 0.33% 2026-07-15
David Thomson
EVP Genl Counsel & Secretary · +254,525 options
Insider 797,554 0.25% 2026-07-15
Steven B. Binder
Director · +127,806 options
Insider 713,258 0.22% 2026-09-25
Sanjay R Singh
EVP Technical Operations · +217,000 options
Insider 478,966 0.15% 2026-07-15
Dominic Marasco
Pres, Endocrine Business Unit
Insider 343,398 0.11% 2026-07-15
Christopher B Prentiss
Chief Financial Officer · +438,000 options
Insider 318,668 0.10% 2026-07-15
Anthony C Hooper
Director · +16,556 options
Insider 236,153 0.07% 2026-03-01
Ronald J Consiglio
Director · +16,556 options
Insider 132,342 0.04% 2026-05-20
Jennifer Grancio
Director · +82,781 options
Insider 110,701 0.03% 2026-05-20

Share count 321,640,118 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-05-29 Afrezza NDA +30.5% +3.6% -3.3%

Browse all historical PDUFA outcomes →

Get the full MNKD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MNKD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.